Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 03, 2022

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes of Bevacizumab Added to Upfront Chemotherapy in Endometrial Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
J. Clin. Oncol 2022 Jun 03;[EPub Ahead of Print], KW Thiel, EJ Devor, VL Filiaci, D Mutch, K Moxley, A Alvarez Secord, KS Tewari, ME McDonald, C Mathews, C Cosgrove, S Dewdney, C Aghajanian, MI Samuelson, HA Lankes, RA Soslow, KK Leslie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading